Pfizer, BioNTech to supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2

This article was originally published here

Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization. The companies will now enter into contract negotiations with the European Commission.

The post Pfizer, BioNTech to supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply